| Email Article | Print |
Motor neuron disease and toxic substances: Possible link?
March 24, 2008Role of abnormal protein in inherited form of MND and in nerve damage caused by chemicals suggests possible gene-environment interactions
Ann Arbor, MI - Motor neuron disease is a rare, devastating illness in which nerve cells that carry brain signals to muscles gradually deteriorate. One form of it, Lou Gehrig's disease or ALS (amyotrophic lateral sclerosis), is familiar to the public in the lives of scientist Stephen Hawking and Morrie Schwartz, about whom Mitch Albom's "Tuesdays with Morrie" was written.
For most MND patients, the cause is unknown. Figuring out why these people develop the disease, which causes muscles to weaken, atrophy and cease to function, is an important step in developing therapies to treat or prevent motor neuron disease.
Now a team of University of Michigan scientists has gotten a step closer:
* They have discovered mutations in one key gene (neuropathy target esterase, or NTE) that cause a previously unknown type of inherited motor neuron disease.
* The discovery paves the way for better diagnosis and research on treatments.
* Most intriguing, the scientists found the mutations caused changes in a protein already known to be involved when people develop neurologic disorders as a result of exposure to toxic organophosphates-chemicals commonly used in solvents and insecticides and also as "nerve gas" agents. This discovery points to a new lead in the search to understand MND.
"We speculate there may be gene-environment interactions that cause some forms of motor neuron disease," says John K. Fink, M.D., professor of neurology at the U-M Medical School and senior author of the new study, which appears in the March issue of the American Journal of Human Genetics. He also is a researcher at the VA Ann Arbor Healthcare System.
"Our findings support the possibility that toxic organophosphates contribute to motor neuron disease in genetically vulnerable people," says Fink. He believes the results suggest that altered activity of the gene found in patients in the study may also contribute to other motor neuron disorders, possibly including ALS. Motor neuron disease affects five per 100,000 people.
The findings are an exciting first step in uncovering a possible link between the environment and motor neuron disease, says Shirley Rainier, a research assistant professor at the U-M Department of Neurology and the first author of the study. "Why does one person in a family get it, and another doesn't?"
Piecing together a puzzle
In the 1930s, an estimated 50,000 people in the U.S. became lame or otherwise neurologically affected by neurotoxic organophosphates when they drank a contaminated batch of "ginger jake," an alcohol-containing potion that was legal during Prohibition.
Ginger jake suppliers substituted a lubricating oil for the oil usually used, castor bean oil, when castor bean prices went up. A 2003 article in the New Yorker detailed the sad results, which led bands like the Mississippi Sheiks to write songs about the "ginger jake blues."
More recently, there have been incidents in Fiji, India and Africa when accidental consumption of oils containing neurotoxic organophosphates (instead of cooking oil) caused death or nerve damage for tens of thousands of people. Although scientists don't yet know the exact manner in which toxic organophosphate exposure leads to progressive and permanent nerve damage, they have learned that this process involves disturbance of an enzyme, NTE, contained within nerves.
Fink examined members of two families who had progressive weakness and spasticity (tightness) in their legs, as well as muscle atrophy in their hands, shins and feet. James Albers, M.D., Ph.D., a U-M professor of neurology and an expert in neuromuscular disorders, studied nerve and motor function. Rainier performed genetic studies and determined that the gene for the condition was on a region of chromosome 19.
Mark Leppert, Ph.D., co-chair of human genetics at the University of Utah, and his team performed genetic analysis that confirmed this location and excluded other areas in the genome. Among the many genes in this region of chromosome 19, one gene stood out as particularly likely: the gene that encodes for NTE. Because of its known role in organophosphate-induced neurological disease, the NTE gene was considered an important candidate gene and was studied immediately.
Analysis showed that the affected people in each family had NTE gene mutations. These mutations altered a critical part of the NTE protein called the esterase domain. Fink has named the inherited condition "NTE motor neuron disease." It begins in childhood and progresses slowly, with symptoms of weakness and spasticity in the legs and muscle atrophy in the hands and lower legs.
Next, Fink and his team want to learn if mutations in the NTE gene happen in other types of motor neuron disease such as ALS, and if the mutations make a person more vulnerable to neurological damage from organophosphate exposure. Fink's lab is currently using fruit flies as a model to study the NTE mutations, with the goal of finding treatments for people with motor neuron disease.
Other authors include Melanie Bui, Erin Mark, Donald Thomas, Debra Tokarz, Lei Ming, Colin Delaney, and James W. Albers, M.D., Ph.D., of the U-M Department of Neurology; Rudy J. Richardson, D.Sc, associate professor of neurology at U-M Medical School and Dow Professor of Toxicology in Environmental Health Sciences at the U-M School of Public Health; and Nori Matsunami, Jeff Stevens, Hilary Coon and Mark Leppert, Ph.D. of the University of Utah.
A patent application for the use of the NTE gene and protein sequence for diagnosis and treatment is pending. The University of Michigan through its Office of Technology Transfer is actively seeking a licensing partner to help bring the technology to market.
Citation: American Journal of Human Genetics, Volume 82, Issue 3, 780-785, 3 March 2008
Funds for this research came from the National Institutes of Health, the Veterans Affairs Merit Review, the U-M Institute of Gerontology, the Spastic Paraplegia Foundation and the National Organization for Rare Disorders.
University of Michigan Health System
Now a team of University of Michigan scientists has gotten a step closer:
* They have discovered mutations in one key gene (neuropathy target esterase, or NTE) that cause a previously unknown type of inherited motor neuron disease.
* The discovery paves the way for better diagnosis and research on treatments.
* Most intriguing, the scientists found the mutations caused changes in a protein already known to be involved when people develop neurologic disorders as a result of exposure to toxic organophosphates-chemicals commonly used in solvents and insecticides and also as "nerve gas" agents. This discovery points to a new lead in the search to understand MND.
"We speculate there may be gene-environment interactions that cause some forms of motor neuron disease," says John K. Fink, M.D., professor of neurology at the U-M Medical School and senior author of the new study, which appears in the March issue of the American Journal of Human Genetics. He also is a researcher at the VA Ann Arbor Healthcare System.
"Our findings support the possibility that toxic organophosphates contribute to motor neuron disease in genetically vulnerable people," says Fink. He believes the results suggest that altered activity of the gene found in patients in the study may also contribute to other motor neuron disorders, possibly including ALS. Motor neuron disease affects five per 100,000 people.
The findings are an exciting first step in uncovering a possible link between the environment and motor neuron disease, says Shirley Rainier, a research assistant professor at the U-M Department of Neurology and the first author of the study. "Why does one person in a family get it, and another doesn't?"
Piecing together a puzzle
In the 1930s, an estimated 50,000 people in the U.S. became lame or otherwise neurologically affected by neurotoxic organophosphates when they drank a contaminated batch of "ginger jake," an alcohol-containing potion that was legal during Prohibition.
Ginger jake suppliers substituted a lubricating oil for the oil usually used, castor bean oil, when castor bean prices went up. A 2003 article in the New Yorker detailed the sad results, which led bands like the Mississippi Sheiks to write songs about the "ginger jake blues."
More recently, there have been incidents in Fiji, India and Africa when accidental consumption of oils containing neurotoxic organophosphates (instead of cooking oil) caused death or nerve damage for tens of thousands of people. Although scientists don't yet know the exact manner in which toxic organophosphate exposure leads to progressive and permanent nerve damage, they have learned that this process involves disturbance of an enzyme, NTE, contained within nerves.
Fink examined members of two families who had progressive weakness and spasticity (tightness) in their legs, as well as muscle atrophy in their hands, shins and feet. James Albers, M.D., Ph.D., a U-M professor of neurology and an expert in neuromuscular disorders, studied nerve and motor function. Rainier performed genetic studies and determined that the gene for the condition was on a region of chromosome 19.
Mark Leppert, Ph.D., co-chair of human genetics at the University of Utah, and his team performed genetic analysis that confirmed this location and excluded other areas in the genome. Among the many genes in this region of chromosome 19, one gene stood out as particularly likely: the gene that encodes for NTE. Because of its known role in organophosphate-induced neurological disease, the NTE gene was considered an important candidate gene and was studied immediately.
Analysis showed that the affected people in each family had NTE gene mutations. These mutations altered a critical part of the NTE protein called the esterase domain. Fink has named the inherited condition "NTE motor neuron disease." It begins in childhood and progresses slowly, with symptoms of weakness and spasticity in the legs and muscle atrophy in the hands and lower legs.
Next, Fink and his team want to learn if mutations in the NTE gene happen in other types of motor neuron disease such as ALS, and if the mutations make a person more vulnerable to neurological damage from organophosphate exposure. Fink's lab is currently using fruit flies as a model to study the NTE mutations, with the goal of finding treatments for people with motor neuron disease.
Other authors include Melanie Bui, Erin Mark, Donald Thomas, Debra Tokarz, Lei Ming, Colin Delaney, and James W. Albers, M.D., Ph.D., of the U-M Department of Neurology; Rudy J. Richardson, D.Sc, associate professor of neurology at U-M Medical School and Dow Professor of Toxicology in Environmental Health Sciences at the U-M School of Public Health; and Nori Matsunami, Jeff Stevens, Hilary Coon and Mark Leppert, Ph.D. of the University of Utah.
A patent application for the use of the NTE gene and protein sequence for diagnosis and treatment is pending. The University of Michigan through its Office of Technology Transfer is actively seeking a licensing partner to help bring the technology to market.
Citation: American Journal of Human Genetics, Volume 82, Issue 3, 780-785, 3 March 2008
Funds for this research came from the National Institutes of Health, the Veterans Affairs Merit Review, the U-M Institute of Gerontology, the Spastic Paraplegia Foundation and the National Organization for Rare Disorders.
University of Michigan Health System
Motor Neuron Disease News and Current Motor Neuron Disease Events RSSResearchers identify a gene responsible for cases of Lou Gehrig's disease
A team of Canadian and French researchers has identified a novel gene responsible for a significant fraction of ALS (sporadic amyotrophic lateral sclerosis) cases. ALS is commonly referred to as Lou Gehrig's disease, an incurable neuromuscular disorder that affects motor neurons and leads to paralysis and death within one to five years.
Hope among patients with ALS may take a variety of forms
Sustaining hope in the face of a chronic, debilitating illness such as amyotrophic lateral sclerosis (ALS) should be a goal of palliative care and can take many forms, representing a continuum from focusing on the self to concern for others.
Understanding the Noxious cause of Lou Gehrig's disease
There is no known cure for amyotrophic lateral sclerosis (ALS), often known as Lou Gehrig disease and motor neuron disease.
U. Iowa team identifies genes that improve survival in mice with ALS
University of Iowa researchers investigating the basic biology of cell signaling have made a discovery that may have therapeutic implications for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Not all embryonic stem cell lines are created equal
When it comes to generating neurons, researchers have found that not all embryonic stem (ES) cell lines are equal. In comparing neurons generated from two NIH-approved embryonic stem cell lines, scientists have uncovered significant differences in the mature, functioning neurons generated from each line.
Discovery of agile molecular motors could aid in treating motor neuron diseases
Over the last several months, the labs of Yale Goldman, MD, PhD, Director of the Pennsylvania Muscle Institute at the University of Pennsylvania School of Medicine, and Erika Holzbaur, PhD, Professor of Physiology, have published a group of papers that, taken together, show proteins that function as molecular motors are surprisingly flexible and agile, able to navigate obstacles within the cell.
Silence the gene, save the cell: RNA interference as promising therapy for ALS
Scientists at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland have used RNA interference in transgenic mice to silence a mutated gene that causes inherited cases of amytrophic lateral sclerosis (ALS), substantially delaying both the onset and the progression rate of the fatal motor neuron disease. Their results will be published in the April issue of Nature Medicine, and in the journal's advanced online publication March 13.
Oxford Biomedica Obtains Further Fundamental Patent For Lentiviral Gene Therapy Technology
Oxford BioMedica plc announced today that it has received allowance from the US Patent Office for a further patent covering its proprietary LentiVector technology. This additional patent compliments the US patent 6,312,682 issued in November 2001 and both include broad composition of matter claims and methods of production claims for lentiviral vector gene delivery systems of both human and non-human origin. This patent adds further strength to Oxford BioMedica's existing patents that cover derivatives of lentiviral vector systems that, unlike many versions of lentiviral vectors, have real clinical utility because of their safety. The Oxford BioMedica team was the first to construct lentivi
The Biochemist, June 2001 Edition, Theme: Take The Strain - Brain Degeneration
Older and wiser - Introduction by Elaine Snell Sadly, in the UK alone, one in every 100 people over the age of 65 years has Parkinson's disease. Globally, the number of people with Alzheimer's disease will double to 30 million in the next 30 years. By the middle of the century, the number of people over the age of 90 years will have trebled. Neurodegenerative diseases are necessarily a major focus of research. The 2000 Nobel Prize for Physiology and Medicine was awarded to Greengard, Kandel and Carlsson for discoveries in neuro-transmission. According to the European Dana Alliance for the Brain, an organization that promotes brain research: "We are at an extraordinarily exciting time in
More Motor Neuron Disease News Articles
 | Motor Neuron Disease (The Facts) by Kevin Talbot, Rachael Marsden |
 | Tomato Juice- A Tribute to my Mom: A Journey about Progressive Bulbar Palsy (ALS) by Diane Hamilton |
 | Motor Neuron Disease: A Family Affair (Overcoming Common Problems) by David Oliver |
 | Motor Speech Disorders by Frederic L. Darley, Arnold Elvin Aronson, Joe Robert Brown |
 | Motor Neuron Disease Research Progress |
 | The Motoneurone and Its Muscle Fibres (Monographs of the Physiological Society) by Daniel Kernell |
 | Clinical Neurophysiology of Motor Neuron Diseases: Handbook of Clinical Neurophysiology |
 | Palliative Care in Amyotrophic Lateral Sclerosis (Motor Neuron Disease) |
 | Motor Neuron Disease by John L.R. Forsythe, Rutherford, Kunel |
 | Motor Neurobiology of the Spinal Cord (Methods and New Frontiers in Neuroscience) |
| © 2008 BrightSurf.com |